Huhtaniska, S, Jaaskelainen, E, Hirvonen, N, Remes, J, Murray, GK, Veijola, J, et al. Long-term antipsychotic use and brain changes in schizophrenia – a systematic review and meta-analysis. Hum Psychopharmacol
2017; 32: e2574.
Chouinard, G, Jones, BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry
1980; 137: 16–21.
Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand
2006; 114: 3–13.
Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med
2012; 42: 2145–55.
Takeuchi, H, Kantor, N, Sanches, M, Fervaha, G, Agid, O, Remington, G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry
2017; 211: 137–143.
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet
2012; 379: 2063–71.
Pigott, TA, Carson, WH, Sana, AR, Torbeyns, AF, Stock, EG, Ingenito, GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry
2003; 64: 1048–56.
Murray, RM, Quattrone, D, Natesan, S, van Os, J, Nordentoft, M, Howes, O, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Br J Psychiatry
2016; 209: 361–5.
Geddes, JR, Carney, SM, Davies, C, Furukawa, TA, Kupfer, DJ, Frank, E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet
2003; 361: 653–61.
Jaaskelainen, E, Juola, P, Hirvonen, N, McGrath, JJ, Saha, S, Isohanni, M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull
2013; 39: 1296–306.
Aastrup, C, Fossum, A, Holmboe, R. Prognosis in Functional Psychoses. Clinical, Social and Genetic Aspects.
Charles C. Thomas, 1962.
Robinson, D, Woerner, MG, Alvir, JM, Bilder, R, Goldman, R, Geisler, S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry
1999; 56: 241–7.
Morgan, C, Lappin, J, Heslin, M, Donoghue, K, Lomas, B, Reininghaus, U, et al. Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 Study. Psychol Med
2014; 44: 2713–26.
Ran, M-S, Weng, X, Chan, CL-W, Chen, EY-H, Tang, C-P, Lin, F-R, et al. Different outcomes of never-treated and treated patients with schizophrenia: 14-year follow-up study in rural China. Br J Psychiatry
2015; 207: 495–500.
Dorph-Petersen, KA, Pierri, JN, Perel, JM, Sun, Z, Sampson, AR, Lewis, DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology
2005; 30: 1649–61.
Ho, BC, Andreasen, NC, Ziebell, S, Pierson, R, Magnotta, V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry
2011; 68: 128–37.
Andreasen, NC, Liu, D, Ziebell, S, Vora, A, Ho, BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry
2013; 170: 609–15.
Lesh, TA, Tanase, C, Geib, BR, Niendam, TA, Yoon, JH, Minzenberg, MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry
2015; 72: 226–34.
Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry
2007; 68: 654–61.
Sampson, S, Mansour, M, Maayan, N, Soares-weiser, K, Adams, CE. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev
2013; 7: CD006196.
Kane, JM, Davis, JM, Schooler, N, Marder, S, Casey, D, Brauzer, B, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry
2002; 159: 554–60.
Wang, CY, Xiang, YT, Cai, ZJ, Weng, YZ, Bo, QJ, Zhao, JP, et al. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. Am J Psychiatry
2010; 167: 676–85.
McGrath, J, Saha, S, Chant, D, Welham, J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev
2008; 30: 67–76.